US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Axsome Therapeutics, Inc. - Common Stock
(NQ:
AXSM
)
179.25
-2.82 (-1.55%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Axsome Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
3 Under-the-Radar Stocks to Buy and Hold for a Decade
↗
June 16, 2026
All three could become highly prominent biotech companies within 10 years.
Via
The Motley Fool
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
June 15, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS Pipeline
↗
June 06, 2026
Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing to launch Auvelity in Alzheimer’s disease agitation this month while continuing to expand the drug’s use in major depressive...
Via
MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Q1 Revenue Beat Misses Estimates as Launch Costs Surge
↗
May 04, 2026
Via
Chartmill
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
June 04, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
June 03, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
June 01, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Participate in Upcoming Investor Conferences
May 27, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting
May 26, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
↗
May 24, 2026
Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch
↗
May 12, 2026
Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing for a June launch of AUVELITY in Alzheimer’s disease agitation while continuing to expand its push in major depressive...
Via
MarketBeat
3 Stocks Poised to Disrupt the Healthcare Market by 2030
↗
May 08, 2026
The old healthcare model is breaking down.
Via
The Motley Fool
Topics
Artificial Intelligence
Axsome Therapeutics Recognizes Mental Health Month
May 07, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
3 Overlooked Stocks Set to Soar in 2026
↗
May 05, 2026
These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.
Via
The Motley Fool
Axsome Therapeutics to Participate in Upcoming Investor Conferences
May 05, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Why Did Axsome Therapeutics Stock Hit Another Record High Today?
↗
May 04, 2026
Investors think a new addition to the biotech's pipeline could be the next catalyst.
Via
The Motley Fool
Axsome (AXSM) Q1 2026 Earnings Call Transcript
↗
May 04, 2026
Axsome (AXSM) Q1 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Axsome (AXSM) Q2 2025 Earnings Transcript
↗
May 04, 2026
Axsome (AXSM) Q2 2025 Earnings Transcript
Via
The Motley Fool
Axsome (AXSM) Q1 2025 Earnings Call Transcript
↗
May 04, 2026
Axsome (AXSM) Q1 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 04, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Why Axsome Therapeutics Stock Jumped Over 20% in April
↗
May 02, 2026
Axsome shares reached an all-time high last month, and there might be more to come.
Via
The Motley Fool
Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader
May 01, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
April 30, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Is This Healthcare Stock a Millionaire Maker?
↗
April 08, 2026
If it can establish itself as a leading biotech in the future, it might be.
Via
The Motley Fool
Topics
Initial Public Offering
Intellectual Property
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
April 01, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now
↗
March 25, 2026
The next 10 months might be challenging for this biotech.
Via
The Motley Fool
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain
↗
March 18, 2026
Axsome Therapeutics develops therapies for central nervous system disorders, with a late-stage pipeline targeting major unmet medical needs.
Via
The Motley Fool
2 Under-the-Radar Stocks to Buy and Hold
↗
March 10, 2026
These biotechs are slowly making a name for themselves.
Via
The Motley Fool
Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision
↗
March 09, 2026
This CNS drug developer with a diverse pipeline just saw a key insider trim their stake, according to recent filings.
Via
The Motley Fool
Topics
Regulatory Compliance
Axsome Therapeutics to Participate in Upcoming Investor Conferences
February 25, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
